- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
30 result(s) found for: Vascularity.
Displaying page 1 of 2.
EudraCT Number: 2005-001977-82 | Sponsor Protocol Number: RA4104917 | Start Date*: 2005-09-09 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dos... | ||
Medical condition: Rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000044-71 | Sponsor Protocol Number: V3Aug2008 | Start Date*: 2006-10-02 |
Sponsor Name:University Hospitals of Leicester NHS Trust Research & Development Department | ||
Full Title: Randomised controlled trial of the effects of fish oil emulsion in total parenteral nutrition upon tumour vascularity in patients with hepatic colorectal metastases | ||
Medical condition: Potentially resectable hepatic (liver) metastases from colorectal (bowel) cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-002536-32 | Sponsor Protocol Number: GREEN-EX | Start Date*: 2023-07-06 | |||||||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||||||||||||
Full Title: Indocyanine green to assess vascularity of ileal conduit anastomosis and regulate ureteral resection margins during pelvic exenteration for recurrent/persistent gynecological cancer. A pilot study | |||||||||||||||||||||||
Medical condition: Patients with gynecological cancers undergoing pelvic exenteration | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000159-15 | Sponsor Protocol Number: PRTK15-TL/SONCHIMIO | Start Date*: 2018-01-12 | ||||||||||||||||
Sponsor Name:CHRU TOURS | ||||||||||||||||||
Full Title: Targeted delivery of chemotherapy with ultrasound and microbubbles | ||||||||||||||||||
Medical condition: Colo-Rectal Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001878-42 | Sponsor Protocol Number: viagra01 | Start Date*: 2018-03-27 | ||||||||||||||||
Sponsor Name:CONSORCIO HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA | ||||||||||||||||||
Full Title: Sildenafil Citrate effect on in vivo human trophoblast research. | ||||||||||||||||||
Medical condition: This is a placebo – controlled longitudinal study to determine whether maternal administration of an unique oral dose of sildenafil citrate (50mg) improves placental flow in first trimester in ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003217-20 | Sponsor Protocol Number: 15073 | Start Date*: 2016-03-23 |
Sponsor Name:University of Nottingham | ||
Full Title: Management of recurrent pterygium to prevent visual impairment(REPEAT) | ||
Medical condition: RECURRENT PTERYGIUM | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004710-33 | Sponsor Protocol Number: CAMEL 02 | Start Date*: 2006-02-24 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PTK787 IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA | ||
Medical condition: Metastatic cutaneous melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004072-35 | Sponsor Protocol Number: 18-AOIP-01 | Start Date*: 2019-02-13 | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Study of the value of early treatment with an endothelin inhibitor (Bosentan) in patients with sudden blindness secondary to giant cell arteritis | |||||||||||||
Medical condition: giant cell arteritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004119-36 | Sponsor Protocol Number: METOXY-LACC | Start Date*: 2019-11-04 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Altered tumor oxygenation by Metformin, a potential step in overcoming radiotherapy resistance in locally advanced cervical cancer. | |||||||||||||
Medical condition: Locally advanced cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017525-19 | Sponsor Protocol Number: 77777 | Start Date*: 2010-03-12 |
Sponsor Name:St. Vincents University Hospital, Department of Rheumatology. | ||
Full Title: Abatacept in Psoriasis and Psoriatic Arthritis: a single centre, placebo-controlled, crossover study in 15 patients. | ||
Medical condition: Psoriatic Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003011-12 | Sponsor Protocol Number: RR08/8613 | Start Date*: 2009-03-30 |
Sponsor Name:University of Leeds | ||
Full Title: Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003216-37 | Sponsor Protocol Number: n.a. | Start Date*: 2015-02-12 |
Sponsor Name: | ||
Full Title: Efficacy of Verapamil/ Verapamil-Kenacort injection versus Kenacort injection in Scar Treatment | ||
Medical condition: Hypertrophic and keloid scars are pathological scars as a result of dermal injury and exhibit exuberant, indefinite growth of collagen during wound healing. Hypertrophic and keloid scars often caus... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001448-29 | Sponsor Protocol Number: 30001 | Start Date*: 2006-09-18 | |||||||||||
Sponsor Name:St Georges Healthcare NHS trust | |||||||||||||
Full Title: A prospective observational cohort study of intra-articular Infliximab in knee mono-arthritis | |||||||||||||
Medical condition: Inflammatory knee mono-arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001317-16 | Sponsor Protocol Number: TRAIN_2019 | Start Date*: 2019-10-30 | ||||||||||||||||
Sponsor Name:ErasmusMC | ||||||||||||||||||
Full Title: The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas | ||||||||||||||||||
Medical condition: Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004896-20 | Sponsor Protocol Number: SPD476-314 | Start Date*: 2008-05-20 | |||||||||||
Sponsor Name:Shire Pharmaceutical Development Limited | |||||||||||||
Full Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence... | |||||||||||||
Medical condition: Treatment of Diverticulitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FI (Completed) DE (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020319-34 | Sponsor Protocol Number: DGD 44-050 | Start Date*: 2010-09-30 | |||||||||||
Sponsor Name:GUERBET | |||||||||||||
Full Title: SAFETY AND EFFICACY EVALUATION OF DOTAREM® IN MAGNETIC RESONANCE IMAGING (MRI) IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) LESIONS | |||||||||||||
Medical condition: Patient with Central Nervous System (CNS) Lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) ES (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003413-18 | Sponsor Protocol Number: IM101 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:King’s College London [...] | |||||||||||||
Full Title: Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept. | |||||||||||||
Medical condition: The target population for therapeutic intervention will be subjects who carry serum autoantibodies (antibodies to citrullinated protein antigens – ACPA; rheumatoid factor – RF) and who have joint p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002462-41 | Sponsor Protocol Number: TBRU-dS-RAC-PII | Start Date*: 2018-10-29 |
Sponsor Name:CUTISS AG | ||
Full Title: A Phase II, prospective, intra-patient randomized controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the... | ||
Medical condition: Adults and children with full thickness skin defects | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022416-40 | Sponsor Protocol Number: 3591 | Start Date*: 2011-09-30 |
Sponsor Name:The Royal Marsden NHS Foundation Trust | ||
Full Title: A Translational, proof of the concept, study Of Pre-operative Pazopanib in treatment-naive patients with resectable soft tissue Sarcomas (TOPPS) | ||
Medical condition: Resectable Soft Tisue Sarcomas (cancer of conective soft tissues) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-004355-37 | Sponsor Protocol Number: B5301001 | Start Date*: 2013-06-04 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06473871 IN REDUCING HYPERTROPHIC SKIN SCARRING | ||
Medical condition: Hypertrophic skin scarring | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) HU (Completed) ES (Completed) NL (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
